Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
203400.KQ
STRONG SELLABION Inc. · Healthcare · South Korea · $54M · Avg Vol: $1M/d
2
StockRankQ
23
V
41
M
10
P/E (TTM)
—
ROE
-63.4%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical...
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 2M | 838,823 | 500,068 | 579,357 | -29.5% |
| EPS | -0.33 | -0.47 | -0.27 | -0.29 | — |
| Shares | 40M | 47M | 61M | 62M | +54.4% |
| Debt | 3M | 10M | 11M | 6M | 22.7% |
| Equity | 10M | 7M | 19M | 45M | 65.4% |
| Op CF | -13M | -18M | -18M | -22M | — |
| Inv CF | 6M | -6M | -3M | 6M | — |
| Fin CF | 61,443 | 28M | 16M | 36M | — |
Loading...
PRICE (1M)-51.8%
SMA 50SMA 200
Close
$0.78
RSI (14)
19.6
52W High
$4.04
From 52W High
0.2%
SCORE BREAKDOWN
Quality
23
ROIC
-34.7%19.5
ROE
-63.4%13.7
GP/Assets
0.1%10.7
Op. Margin
-1139.7%6.7
FCF/Assets
-35.5%6.8
Piotroski
—7.2
Int. Cover
-6.9x28.2
D/E Ratio
0.15x59.2
Current Ratio
3.37x57.8
Value
41
P/E (TTM)
—N/A
EV/EBITDA
-5.1x73.6
P/FCF
—N/A
P/B
1.1x76.1
P/S
80.2x8.0
Div Yield
—N/A
Momentum
10
52W High %
19%2.1
RS 6M
-181%0.2
SMA 50/200
0.77x10.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$54M
P/E (Forward)
—
Gross Margin
11.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 203400.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 203400.KQ | ABION Inc.(you) | $54M | 2 | STRONG SELL |
| 011000.KS | GeneOne Life Science, Inc. | $68M | 1 | STRONG SELL |
| 456070.KQ | ENCell | $63M | 5 | STRONG SELL |
| 323990.KQ | Vaxcell-Bio Therapeutics Co., Ltd. | $88M | 2 | STRONG SELL |
| 166480.KQ | CORESTEMCHEMON Inc. | $69M | 9 | STRONG SELL |
| 235980.KQ | MedPacto, Inc. | $80M | 6 | STRONG SELL |
| 048530.KQ | iNtRON Biotechnology, Inc. | $53M | 17 | STRONG SELL |
| 389030.KQ | GENINUS Inc. | $74M | 14 | STRONG SELL |
| 095700.KQ | Genexine, Inc. | $111M | 7 | STRONG SELL |
| 338840.KQ | Y-Biologics | $136M | 3 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%